CSX — CSX CORP SEC Filings

Date	Insider	Action	Shares	Price	Value
Mar 6, 2026	Angel Stephen FPresident & CEO	Buy	25,000	$40.27	$1.0M
Feb 19, 2026	Sorfleet Diana BEVP & CAO	Sell	90,000	$41.56	$3.7M
Feb 3, 2026	Fortune StephenEVP - CD & TO	Sell	31,456	$38.65	$1.2M
Jan 28, 2026	Sorfleet Diana BEVP & CAO	Sell	66,667	$37.48	$2.5M
Oct 22, 2025	Boone Kevin S.EVP & CCO	Sell	31,053	$36.09	$1.1M
Oct 20, 2025	Angel Stephen FPresident & CEO	Buy	55,000	$36.87	$2.0M
Oct 20, 2025	Burns Michael S.SVP - CLO & Corp Secy	Sell	24,249	$36.76	$891K

What Changed

Risk factors · Feb 27, 2025 → Feb 12, 2026

52 added · 50 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.

Newly disclosed

Years Ended (Dollars in Millions) 2025 2024 2023 Share-Based Compensation Expense Restricted Stock Units $ 26 $ 28 $ 19 Stock Options 14 12 12 Employee Stock Purchase Plans 10 8 7 Stock Awards for Directors 3 2 2 Performance Units 1 ( 10 ) 20 Total Share-based Compensation Expense $ 54 $ 40 $ 60 Income Tax Benefit $ 13 $ 13 $ 14 CSX 2025 Form 10-K p.64 CSX CORPORATION PART II Item 8.
Impairment expense recorded in purchased services and other expense on the consolidated income statement of $ 26 million in 2025, $ 24 million in 2024, and $ 2 million in 2023 was primarily due to the discontinuation of certain in-progress projects.
This guidance is effective beginning first quarter 2029, though early adoption is permitted, and can be applied using a modified prospective, modified retrospective, or full retrospective transition approach.
This guidance is effective beginning first quarter 2028, though early adoption is permitted, and can be applied using a prospective, retrospective, or modified transition approach.
Years Ended 2025 2024 2023 Antidilutive Stock Options Excluded from Diluted EPS (Units in Millions) 5 3 3 CSX 2025 Form 10-K p.62 CSX CORPORATION PART II Item 8.
Years Ended (Dollars in Millions) 2025 2024 2023 Amounts Paid $ 456 $ 311 $ 236 CSX 2025 Form 10-K p.82 CSX CORPORATION PART II Item 8.
CSXT, on behalf of Pharmacia, and a significant number of other potentially responsible parties are together conducting a Remedial Investigation and Feasibility Study of the Study Area pursuant to an Administrative Settlement Agreement and Order on Consent with the EPA.
The Company adopted this guidance prospectively for this 2025 annual report filed on Form 10-K.
Pharmacia’s share of responsibility, indemnified by CSXT, for the investigation and cleanup costs of the Study Area may be determined through various mechanisms including (a) an allocation and settlement with EPA;
Performance Units In 2025, 2024 and 2023, target performance units, with each unit being equivalent to one share of CSX common stock, were granted to certain employees under three separate LTIP plans covering three-year cycles: the 2025-2027 ("2025-2027 LTIP"), the 2024-2026 ("2024-2026 LTIP"), and the 2023-2025 ("2023-2025 LTIP").
Performance unit grants were valued using the following weighted-average assumptions: Years Ended Weighted-Average Assumptions Used: 2025 2024 2023 Risk-free Interest Rate 4.1 % 4.4 % 4.4 % Annualized Volatility 23.3 % 23.3 % 33.2 % Expected Life (in years) 2.7 2.9 2.8 The risk-free interest rate assumptions reflect the U.S.
The 2025 payment amount includes a $ 96 million prepayment for 2026 locomotive maintenance services, which is included in other current assets on the consolidated balance sheet, as well as $ 14 million for pre-owned locomotives received in 2025.

No longer disclosed

The Company adopted this guidance for this 2024 annual report filed on Form 10-K and the standard update did not impact the Company's results of operations or financial position as the update only impacts disclosures.
Impairment expense of $ 24 million in 2024, $ 2 million in 2023, and $ 4 million in 2022 was primarily due to the discontinuation of certain in-progress projects.
Environmental reserves include liabilities assumed as a result of entities acquired by the Company, including the acquisition of Pan Am in 2022.
Other reserves include liabilities assumed as a result of entities acquired by the Company, including the acquisition of Pan Am in 2022.
The Company is required to adopt the guidance for its 2025 annual report filed on Form 10-K, though early adoption is permitted.
Casualty reserves include liabilities assumed as a result of the Company's acquisition of Pan Am in 2022.
Revision of Prior Period Financial Statements During second quarter 2024, CSX completed a review of the accounting treatment for engineering scrap and certain engineering support labor and identified misstatements between the balance sheet and operating expense in previously issued financial statements.
Years Ended 2024 2023 2022 Antidilutive Stock Options Excluded from Diluted EPS (Units in Millions) 3 3 3 Share Repurchase Programs During fourth quarter 2023, the share repurchase program announced in July 2022 was completed and the Company began repurchasing shares under the $ 5 billion share repurchase program approved in October 2023.
Years Ended (Dollars in Millions) 2024 2023 2022 Share-Based Compensation Expense Restricted Stock Units $ 28 $ 19 $ 15 Stock Options 12 12 17 Employee Stock Purchase Plans 8 7 5 Stock Awards for Directors 2 2 2 Performance Units ( 10 ) 20 35 Total Share-based Compensation Expense $ 40 $ 60 $ 74 Income Tax Benefit $ 13 $ 14 $ 17 Long-term Incentive Plans The objective of the CSX Long-term Incentive Plans (“LTIP”) is to motivate and reward certain employees for achieving and exceeding certain financial goals.

CSX CORP

Similar companies

Insider Activity

In the News

What Changed